OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Infectious Diseases is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review	556
Airborne or Droplet Precautions for Health Workers Treating Coronavirus Disease 2019?	299
Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019	283
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces	261
Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review	258
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China	254
ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19	254
Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient	242
COVID-19 Pandemic: Disparate Health Impact on the Hispanic/Latinx Population in the United States	238
Exportation of Monkeypox Virus From the African Continent	225
On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community	224
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells	216
Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients	215
Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays	191
S-Variant SARS-CoV-2 Lineage B1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction	186
Airborne SARS-CoV-2 Is Rapidly Inactivated by Simulated Sunlight	186
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection	174
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection	174
Attenuated Interferon and Proinflammatory Response in SARS-CoV-2–Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation	161
Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients	160
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities	156
Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections	139
Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2	136
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion	133
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy	121

T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019	120
Severe Acute Respiratory Syndrome Coronavirus 2–Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells	120
Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection	118
A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019	116
Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis	115
SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence	115
Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda	113
Human Rhinovirus Infection Blocks Severe Acute Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium: Implications for COVID-19 Epidemiology	113
Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019	107
Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 Infection	106
Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco	106
Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19	105
Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019	105
Racial Disparity of Coronavirus Disease 2019 in African American Communities	99
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model	96
SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors	91
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome	90
Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Ser	87
Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium	85
Direct Observation of Repeated Infections With Endemic Coronaviruses	84
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines	84
Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes	84
Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015	80
A Granulocytic Signature Identifies COVID-19 and Its Severity	79
Early Differences in Cytokine Production by Severity of Coronavirus Disease 2019	79
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy	78
Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome	77
Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2–Related Encephalitis: The ENCOVID Multicenter Study	77
Global Seasonality of Human Seasonal Coronaviruses: A Clue for Postpandemic Circulating Season of Severe Acute Respiratory Syndrome Coronavirus 2?	77
Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?	76
Hepatitis B Vaccines	75
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019	74
The Concept of Classical Herd Immunity May Not Apply to COVID-19	74
Responding to Outbreaks of Human Immunodeficiency Virus Among Persons Who Inject Drugs—United States, 2016–2019: Perspectives on Recent Experience and Lessons Learned	73
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083	73
Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics	72
Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19	71
Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results	70
Nonpharmaceutical Interventions Used to Control COVID-19 Reduced Seasonal Influenza Transmission in China	69
Herpes Zoster Vaccines	67
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine	67
Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus	67
Association Between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients With SARS-CoV-2 Infection	64
Projected HIV and Bacterial Sexually Transmitted Infection Incidence Following COVID-19–Related Sexual Distancing and Clinical Service Interruption	63
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants	63
High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts	63
Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers	62
Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	62
Shifting Patterns of Respiratory Virus Activity Following Social Distancing Measures for Coronavirus Disease 2019 in South Korea	61
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2	61

The Gut Microbiome as a Reservoir for Antimicrobial Resistance	61
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults	61
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic	60
Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study	60
Neutralizing Antibody Responses in COVID-19 Convalescent Sera	60
Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19	60
Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests	59
Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection	58
Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice	58
Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses	58
Human Papillomavirus Vaccines	57
Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19	57
Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2	56
Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy	56
Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic	56
Environmental and Aerosolized Severe Acute Respiratory Syndrome Coronavirus 2 Among Hospitalized Coronavirus Disease 2019 Patients	56
Pathogens Associated With Linear Growth Faltering in Children With Diarrhea and Impact of Antibiotic Treatment: The Global Enteric Multicenter Study	55
Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance	54
Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship	54
Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B	52
COVID-19 Vaccines: Should We Fear ADE?	52
Invasive Candidiasis Species Distribution and Trends, United States, 2009–2017	52
Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion	51
Natural History of Coronavirus Disease 2019: Risk Factors for Hospitalizations and Deaths Among >26 Million US Medicare Beneficiaries	51
High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine	51
Why Does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in Coronavirus Disease 2019	51
The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade	50
Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection	50
Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting	50
A Critical Analysis of the Literature on Time-to-Antibiotics in Suspected Sepsis	49
Ethical Implementation of Immunity Passports During the COVID-19 Pandemic	49
Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review	48
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection	48
SARS-CoV-2 Placentitis Associated With B.1.617.2 (Delta) Variant and Fetal Distress or Demise	47
Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing	47
Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats	47
SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up	47
Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ Between Patients With Mild and Severe/Critical Coronavirus Diseas	47
Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children	46
Understanding the Potential Drivers for Respiratory Syncytial Virus Rebound During the Coronavirus Disease 2019 Pandemic	46
Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets	45
SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline	45
Sepsis and the Microbiome: A Vicious Cycle	44
High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019	44
Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009–2019: A Study of the National (Nationwide) Inpatient Sample	44
Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients	44
Impact of Nonpharmaceutical Interventions for Severe Acute Respiratory Syndrome Coronavirus 2 on Norovirus Outbreaks: An Analysis of Outbreaks Reported By 9 US States	44
A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis	43
Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection	42
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020	42
Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19	42
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination	42
Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys	41
Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea	41
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study	41
Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection	41
Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019	41
Quantifying the Impact of COVID-19 Nonpharmaceutical Interventions on Influenza Transmission in the United States	40
Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization	40
Infectious Diseases and Injection Drug Use: Public Health Burden and Response	40
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine	40
Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus	40
National Public Health Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug Use: A Review	40
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B	40
Location Matters: Geographic Disparities and Impact of Coronavirus Disease 2019	39
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial	39
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination	39
Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study	38
Review of Issues on Residual Malaria Transmission	38
Severe Acute Respiratory Syndrome Coronavirus 2 Total and Subgenomic RNA Viral Load in Hospitalized Patients	38
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post–COVID-19 Convalescent Samples	38
Respiratory Syncytial Virus–Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis	37
Necrotizing Enterocolitis and the Microbiome: Current Status and Future Directions	36
Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection	36
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine	36
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults	36
Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management	35
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities	35
Prevention of Coronavirus Disease 2019 Among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions Between Streptococcus pneumoniae and Severe Acute Respiratory Syndrome C	35
Addressing Ethical Challenges in US-Based HIV Phylogenetic Research	35

Long-term Survival of SARS-CoV-2 on Salmon as a Source for International Transmission	34
Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19	34
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience	34
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit	34
No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic	34
Recommendations for Screening and Diagnosis of Chagas Disease in the United States	34
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model	34
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084	34
Navigating the Uncertainties of COVID-19–Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis	34
Feasibility and Safety of Outpatient Parenteral Antimicrobial Therapy in Conjunction With Addiction Treatment for People Who Inject Drugs	33
Group Testing for Severe Acute Respiratory Syndrome– Coronavirus 2 to Enable Rapid Scale-up of Testing and Real-Time Surveillance of Incidence	33
Estimation Without Representation: Early Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Studies and the Path Forward	33
Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure	33
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019	33
Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis	33
Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients	33
Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro	33
Sensitive, Highly Multiplexed Sequencing of Microhaplotypes From thePlasmodium falciparumHeterozygome	32
Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2	32
Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination	32
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial	32
Comparable Environmental Stability and Disinfection Profiles of the Currently Circulating SARS-CoV-2 Variants of Concern B.1.1.7 and B.1.351	32
Five Years of GenoTyphi: Updates to the Global Salmonella Typhi Genotyping Framework	31
The Block-and-Lock Strategy for Human Immunodeficiency Virus Cure: Lessons Learned from Didehydro–Cortistatin A	31
Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection	31
SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study	31
Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis	31
Influence of Storage Conditions on SARS-CoV-2 Nucleic Acid Detection in Throat Swabs	31
Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors	31
SARS-CoV-2 Infection During Pregnancy and Associated Perinatal Health Outcomes: A National US Cohort Study	31
Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Resp	30
Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults	30
Prospective Study Comparing Deep Throat Saliva With Other Respiratory Tract Specimens in the Diagnosis of Novel Coronavirus Disease 2019	30
Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019	30
Extended ORF8 Gene Region Is Valuable in the Epidemiological Investigation of Severe Acute Respiratory Syndrome–Similar Coronavirus	30
Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age	30
COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men	30
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron	29
Durability of SARS-CoV-2–Specific T-Cell Responses at 12 Months Postinfection	29
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review a	29
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1–Exposed Newborn Infants	29
Risk Factors for Poor Outcome or Death in Young Children With Respiratory Syncytial Virus–Associated Acute Lower Respiratory Tract Infection: A Systematic Review and Meta-Analysis	29
Pertussis (Whooping Cough)	29
A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults	29
Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis	29
Pelvic Inflammatory Disease Due to Neisseria gonorrhoeae and Chlamydia trachomatis: Immune Evasion Mechanisms and Pathogenic Disease Pathways	29
Viral Load of Severe Acute Respiratory Syndrome Coronavirus 2 in Adults During the First and Second Wave of Coronavirus Disease 2019 Pandemic in Houston, Texas: The Potential of the Superspreader	29
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey	29
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection: A Preliminary Report	29
The Issue of Recurrently Positive Patients Who Recovered From COVID-19 According to the Current Discharge Criteria: Investigation of Patients from Multiple Medical Institutions in Wuhan, China	29
Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection	29
CoVA: An Acuity Score for Outpatient Screening that Predicts Coronavirus Disease 2019 Prognosis	28
Burden of Respiratory Syncytial Virus Infection During the First Year of Life	28
Transient Lymphopenia and Interstitial Pneumonia With Endotheliitis in SARS-CoV-2–Infected Macaques	28
Increased Dengue Transmissions in Singapore Attributable to SARS-CoV-2 Social Distancing Measures	28
Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019	28
The Clinical and Economic Burden of Norovirus Gastroenteritis in the United States	28
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicro	28
Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After Discharge in Wuhan, China	28
Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018	28
Coronavirus Disease 2019 Epidemic Doubling Time in the United States Before and During Stay-at-Home Restrictions	27
The Lung Microbiome and Pneumonia	27
The Fibrosis-4 Index Is Associated With Need for Mechanical Ventilation and 30-Day Mortality in Patients Admitted With Coronavirus Disease 2019	27
Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019	27
Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019–2020	27
SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model	27
Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators	27
A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy	27
Rapid, Sensitive, and Specific Severe Acute Respiratory Syndrome Coronavirus 2 Detection: A Multicenter Comparison Between Standard Quantitative Reverse-Transcriptase Polymerase Chain Reaction and CRI	26
Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndro	26
A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy	26
Influenza Vaccines: Successes and Continuing Challenges	26
Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey	25
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Protein	25
Dynamics of Pneumococcal Carriage in Adults: A New Look at an Old Paradigm	25
SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters	25
Human Immunodeficiency Virus/AIDS in the Era of Coronavirus Disease 2019: A Juxtaposition of 2 Pandemics	25
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine	25
Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity	25
Higher Viral Load Drives Infrequent Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Between Asymptomatic Residence Hall Roommates	25
Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication	24
Hepatitis A Person-to-Person Outbreaks: Epidemiology, Morbidity Burden, and Factors Associated With Hospitalization—Multiple States, 2016–2019	24
Morphological and Transcriptional Changes in Human Bone Marrow During Natural Plasmodium vivax Malaria Infections	24
Role of Rapid Diagnostics in Diagnosis and Management of Patients With Sepsis	24
A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics	24
Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p	24
Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review	24
Benefits of Aerosolized Phages for the Treatment of Pneumonia Due to Methicillin-ResistantStaphylococcus aureus: An Experimental Study in Rats	24
Under the Radar: Epidemiology of Plasmodium ovale in the Democratic Republic of the Congo	24
Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity	24
The Global Landscape of Pediatric Bacterial Meningitis Data Reported to the World Health Organization–Coordinated Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2014–2019	24
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible	24
Predicting Vibrio cholerae Infection and Disease Severity Using Metagenomics in a Prospective Cohort Study	23
Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination	23
Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years	23